Synovial Sarcoma - Online Support Group

ImmTAC from Immunocore


Immunocore has designed a molecule for immunotherapy intended to be tried in synovial sarcoma among others. They call it GSK#1 for now and next step is phase 1 trial:
The company is collaborating with GSK on this:

The molecule is an ImmTAC (Immune-mobilizing monoclonal TCRs against Cancer) and it looks like it will target NY-ESO-1 expressing tumors which are also HLA-A*0201-positive: